Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results from a minipig Dose Range Finding ("DRF") study for Probudur. Probudur is the company's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The DRF study was conducted to evaluate the tolerance of Probudur in an incisional wound healing model in minipigs. Probudur was injected locally into the tissue surrounding the incision area. All of th

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a company specializing in developing pharmaceutical products for pain management, announced that it has been granted an extension of its cooperative research and development agreement with the National Center for Advancing Translational Sciences (NCATS), an institute/center of the National Institutes of Health (NIH), U.S. Department of Health and Human Services. This collaboration is for the continued development of Virpax's product candidate, NES100, an intranasal peptide, for the management of acute and chronic non-cancer pain. NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach.

New York, NY, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Spartan Capital Securities, LLC, a leading investment banking firm, is pleased to announce its role as the sole placement agent in Virpax Pharmaceuticals, Inc.'s (NASDAQ:VRPX) successful $5.0 million public offering of common stock and pre-funded warrants. Virpax Pharmaceuticals, a preclinical-stage pharmaceutical company focused on developing novel and proprietary drug delivery systems across various pain indications, raised $5.0 million through the sale of shares of common stock and pre-funded warrants at a public offering price of $0.50 per share. The company intends to use the proceeds for ongoing activities, including its planned Invest

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the closing of its public offering of $5.0 million of shares of the Company's common stock, par value $0.00001 per share, and pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pre-funded warrant). The Company intends to use the proceeds of the offering to fund the Company's ongoing activities, in connection with its planned investigational new drug (IND) filing for its proprietary patented injectable "loca

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) ("Virpax" or the "Company"), a preclinical-stage pharmaceutical company focused in novel and proprietary drug delivery systems across various pain indications, announced today the pricing of its public offering of $5.0 million of shares of the Company's common stock, par value 0.00001 per share, and/or pre-funded warrants to purchase shares of common stock at a public offering price of $0.50 per share (minus $0.00001 per pre-funded warrant). The Company intends to use the proceeds of the offering to fund the Company's ongoing activities, in connection with its planned investigational new drug (IND) filing for its proprietary patented injectable "lo

GLEN ALLEN, Va., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company's Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical, biopharmaceutical, and healthcare sectors, specializing in financial strategy, investor relations, and operational efficiency. Most recently, Mr. Shah served as the CFO at Virpax Pharmaceuticals, Inc. (N

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended June 30, 2024, and other recent developments. "After successful meetings at BIO in San Diego, we remain encouraged by the progress we have made in advancing our product candidates, identifying and applying for additional grants, and engaging in discussions for licensing and other opportunities with a steady stream of potential new partners," stated Gerald W. Bruce, CEO of V

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced that Gerald W. Bruce, CEO, will present and host one-on-one meetings with investors at the Sidoti August Virtual Investor Conference, taking place on August 14-15, 2024. Joining him will be Vinay Shah, CFO. The presentation will begin at 2:30 PM (ET) on Wednesday, August 14th, and can be accessed live here: https://sidoti.zoom.us/webinar/register/WN_BEdsmtAvSLKxmX8cn7Uv7g. Virpax will also host virtual one-on-ones wi

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, announced today that it has received formal notice from the Listing Qualifications staff of The Nasdaq Stock Market LLC indicating that Virpax has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). To regain compliance with the Rule, the Company's common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which w

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, today announced results for a Swine Model pilot study for Probudur, Virpax's long-acting liposomal bupivacaine formulation injected at a wound site to provide both immediate and extended pain relief. The pharmacokinetics (PK) and safety study of Probudur in the Swine Model was designed to determine the PK profile of Probudur as well as to ascertain any adverse effects on the pigs. Probudur was subcutaneously injected into 4 juvenile

S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

S-1/A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

S-1 - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

DEF 14A - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

8-K - Virpax Pharmaceuticals, Inc. (0001708331) (Filer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

4 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

4 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

4 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

3 - Virpax Pharmaceuticals, Inc. (0001708331) (Issuer)

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2024, and other recent developments. "We recently reported results for a Probudur™ Maximum Tolerated Dose Study, as we continue to make steady progress in anticipation of filing our IND. The results of this study, as expected, confirmed our belief that a single injection of Probudur was well-tolerated. Our studies to date continue to reaffirm our belief that Probu

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the twelve months ended December 31, 2023, and other recent developments. "We are off to a strong start in 2024 and are pleased to have regained compliance with Nasdaq. Additionally, we have executed a settlement agreement with the Plaintiffs, and can now focus on developing our non-addictive product candidates for pain management," commented Gerald W. Bruce, Chief Executive Officer of Virpax.

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended September 30, 2023, and other recent developments. "We recently announced results from two preclinical studies for Probudur™, our lead product candidate for post operative pain, that demonstrated significantly longer efficacy in animal models than the product currently on the market today. With these solid results, we believe we are on track to file our Investigational New

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended June 30, 2023, and other recent developments. "In the second quarter, we continued to make progress with our Rx product candidates," commented Anthony P. Mack, Chairman and Chief Executive Officer of Virpax. "As well, we strengthened the organization with the appointment of a new Chief Financial Officer (CFO), who aside from his experience with public biotech companies has

Virpax® Pharmaceuticals, Inc. ("Virpax" or the "Company") (NASDAQ:VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and viral barrier indications, today announced its financial results for the three months ended March 31, 2023, and other recent developments. "Many of the initiatives that we have been actively working on were completed in the first quarter, and I believe that we are off to an excellent start in 2023," commented Anthony P. Mack, Chairman and Chief Executive Officer of Virpax. "We have built up our development teams with the addition of world-class experts to advise u